Back to Agendas
[V4-S4] Future Perspective of Personalized Medicines in Oncology Disease Area - Can You Imagine How NGS Technology is Being Expanded in Japan? -
Session Chair(s)
Tomoko Hirohashi, PhD
Director, Clinical Research Oncology
Pfizer Japan Inc., Japan
Scientific technology has significantly improved, and understanding of molecular mechanisms of cancer has increased considerably. With these changes, the technology for biomarker investigations or diagnostic method has been also improved. The representative example is next generation sequencing (NGS) technology. However there are lots of challenges to be cleared for its clinical and practical use whereas next generation sequencing will have a lot of potential. In this session, we will discuss the options to use this new technology for cancer patients.
Speaker(s)
Future Perspective of Personalized Medicines in Oncology Disease Area - Can You Imagine How NGS Technology is Being Expanded in Japan?
Tomoko Hirohashi, PhD
Pfizer Japan Inc., Japan
Director, Clinical Research Oncology
Activities on Academia of Clinical Sequencing with NGS from the Experience of Clinical Development of Multiplex Diagnostic Kit
Takayuki Yoshino, MD, PhD
National Cancer Center Hospital East, Japan
Department of Gaestrointestinal Oncology
Expectation and Challenge of Implementation for Multiple Marker and NGS - View Points of Both Drug and Diagnostic Companies
Mariko Yamaguchi
QIAGEN K.K., Japan
Senior Manager, RA/QA and Clinical Affairs,
Implementation of Clinical Sequencing in Kyoto University
Manabu Muto, MD, PhD
Graduate School of Medicine, Kyoto University, Japan
Professor, Department of Therapeutic Oncology, Graduate School of Medicine
Have an account?